Introduction

In a closely watched intellectual property dispute before the Court of Justice of São Paulo, a declaratory judgment action brought by Scitech Produtos Médicos S.A. against Cilag GmbH International and Ethicon Endo-Surgery Inc. concluded on August 28, 2024, with an appellate ruling that partially favored the plaintiff. The court’s decision notably increased plaintiffs’ attorneys’ fees to 13% of the conviction imposed on the defendant, applying Article 85, Paragraph 11 of the Brazilian Code of Civil Procedure.

This case — filed under Case No. 1132420-11.2021.8.26.0100 — centers on Brazilian Patent BRPI0807365B1, covering cryptographic identification technology embedded in surgical instruments. For patent litigators, in-house IP counsel, and R&D professionals operating in the medical device sector, the outcome carries meaningful lessons about declaratory judgment strategy, fee-shifting mechanisms in Brazilian courts, and the commercial risks attached to interchangeable surgical instrument components.

The dispute reflects growing litigation pressure in the high-value surgical tools market, where IP portfolios are aggressively defended by multinational players like Ethicon — a Johnson & Johnson subsidiary — against regional manufacturers.

Case Overview

The Parties

The Patent at Issue

The patent in dispute — BRPI0807365B1 — covers technology related to the cryptographic identification of interchangeable surgical instrument components. In practical terms, this patent protects a system by which surgical instruments electronically identify and authenticate interchangeable end-pieces or attachments, using embedded cryptographic or electrical identification mechanisms. Such technology is commercially significant: it governs compatibility between surgical handpieces and their interchangeable tips, creating substantial market control over consumable surgical components.

The product category identified in the record is described as a “surgical instrument identification cryptographic sustaining electrically-piece interchangeable” — referring to a system or component that enables electronic identification and authentication of interchangeable surgical instrument pieces. This type of technology has direct commercial implications for device compatibility, reprocessing practices, and the aftermarket surgical instrument industry.

Legal Representation

Specific law firms and attorneys of record were not disclosed in the available case data.

Litigation Timeline & Procedural History

The case was filed in 2021 before the Court of Justice of São Paulo (Case No. 1132420-11.2021.8.26.0100) and proceeded through the appellate tier before closing on August 28, 2024. The classification of the trial level as “other” in the record suggests the matter was resolved at an appellate or specialized chamber level within the São Paulo state court system, which handles significant commercial and IP matters in Brazil’s largest judicial district.

The São Paulo Court of Justice is a critical venue for Brazilian IP litigation, given the concentration of multinational corporations and technology companies in the state. Declaratory judgment actions in this court allow parties — particularly manufacturers facing infringement threats — to proactively seek legal certainty regarding patent validity or non-infringement before formal infringement proceedings are initiated by rights holders.

The duration of the proceedings, spanning approximately three years from filing to closure, reflects the complexity typical of patent-related declaratory actions involving technically sophisticated subject matter and multinational defendants with substantial litigation resources.

No specific intermediate milestones — such as preliminary injunctions, claim construction hearings, or summary judgment motions — are disclosed in the available record.

The Verdict & Legal Analysis

Outcome

The appellate court issued a partial grant of the appeal. The most consequential procedural ruling was the increase in plaintiffs’ attorneys’ fees to 13% of the conviction imposed on the defendant, applied pursuant to Article 85, Paragraph 11 of the Brazilian Code of Civil Procedure. The appeal was otherwise dismissed on its known grounds. The verdict cause is classified as a Declaratory Judgment, and the basis of termination is recorded as Appeal Granted in Part.

Specific damages amounts beyond the attorneys’ fee adjustment were not disclosed in the available case data.

Verdict Cause Analysis

The declaratory judgment framework in Brazilian civil procedure allows a party — here, Scitech — to seek judicial confirmation of a legal situation, such as the non-existence of an infringement obligation or the invalidity of a patent claim as applied to their products. By bringing this action, Scitech positioned itself as the proactive party, likely seeking to neutralize an infringement threat or assertion made by Cilag/Ethicon regarding patent BRPI0807365B1.

The appellate court’s decision to partially grant the appeal while dismissing the remainder indicates a nuanced merits assessment. The specific legal ground triggering the fee increase — Article 85, §11 of the CPC — applies when a lower court’s fee award is challenged on appeal, allowing appellate courts to revise fee percentages upward. This is a procedurally significant mechanism that patent litigators practicing in Brazil must carefully account for when advising clients on appeal strategies.

Legal Significance

The application of Article 85, §11 CPC to increase attorneys’ fees on appeal is a meaningful signal for IP litigants in Brazil. Courts retain discretion to revise fee awards upward when appeals are pursued without sufficient merit on all grounds, effectively penalizing appellants who partially succeed but fail on core claims. For multinational defendants facing declaratory actions in Brazil, this creates real financial exposure beyond the merits of the underlying IP dispute.

The BRPI0807365B1 patent’s focus on cryptographic authentication of surgical instrument components places it at the intersection of software-embedded hardware IP — a category subject to evolving claim construction standards globally. How Brazilian courts interpret the scope of such claims will influence both prosecution strategy for similar patents and freedom-to-operate analyses for medical device manufacturers active in Brazil.

Strategic Takeaways

For Patent Holders (Cilag/Ethicon): Multinational rights holders asserting patents against Brazilian manufacturers should anticipate declaratory judgment countermoves. Robust pre-litigation due diligence and a clearly scoped claim portfolio reduce exposure to adverse declaratory rulings.

For Accused Infringers/Declaratory Plaintiffs (Scitech): Proactive declaratory judgment filings in São Paulo can be an effective strategy to control litigation timing and venue. Partial appellate success — even on procedural grounds like fee recovery — can meaningfully shift the economic calculus of litigation.

For R&D Teams: The cryptographic identification claims in BRPI0807365B1 highlight the importance of conducting freedom-to-operate (FTO) analyses before commercializing interchangeable surgical component systems. Authentication and identification mechanisms embedded in medical hardware increasingly attract patent protection globally.

Industry & Competitive Implications

The Scitech v. Cilag/Ethicon dispute reflects a broader competitive tension in the global surgical instruments market, where manufacturers of interchangeable components and consumables frequently clash with OEM platform holders over IP covering identification and compatibility technologies. Ethicon’s market position depends substantially on controlling the ecosystem of compatible surgical components — a strategy enforced, in part, through IP assets like BRPI0807365B1.

For Brazilian and Latin American medical device manufacturers, this case demonstrates both the viability of challenging multinational IP holders through declaratory proceedings and the legal tools available — including appellate fee recovery — to impose economic consequences on overreaching assertions.

The outcome also reflects the maturation of Brazilian IP litigation infrastructure. The São Paulo Court of Justice’s engagement with technically complex patent matters involving cryptographic hardware systems signals that Brazilian courts are increasingly equipped to adjudicate sophisticated IP disputes, making Brazil a meaningful jurisdiction for IP portfolio strategy in the Americas.

Companies operating in the surgical instruments space — particularly those developing interchangeable tool platforms — should monitor BRPI0807365B1’s claim scope and any related prosecution history at the Brazilian Patent Office (INPI) to assess competitive exposure.